All data are based on the daily closing price as of December 24, 2024
h

HK inno.N

195940.KQ
24.91 USD
0.03
+0.12%

Overview

Last close
24.91 usd
Market cap
705.73M usd
52 week high
37.81 usd
52 week low
23.96 usd
Target price
42.54 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
1.2265
Price/Book Value
0.8257
Enterprise Value
930.01M usd
EV/Revenue
1.5326
EV/EBITDA
16.0911

Key financials

Revenue TTM
575.41M usd
Gross Profit TTM
N/A usd
EBITDA TTM
65.37M usd
Earnings per Share
N/A usd
Dividend
0.24 usd
Total assets
1,884.12B usd
Net debt
N/A usd

About

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition. It also provides health and beverage products, such as hangover relief, ready to drink, health supplements and health functional foods, as well as active pharmaceutical ingredients. In addition, the company offers beauty products under the bewants, ScalpMed, and KLEDERMA RX brands. It also exports its products to Japan, Southeast Asia, Latin America, Europe, and the Middle East countries. HK inno.N Corporation was founded in 1984 and is headquartered in Cheongju-si, South Korea.
  • Symbol
    195940.KQ
  • Exchange
    KQ
  • Isin
    N/A
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Dal-Won Kwak
  • Headquarter
    Cheongju-si
  • Web site
    https://www.inno-n.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top